Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

• Status: Recruiting
• Trial end date: 2026-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of docetaxel and cisplatin combined with Nimotuzumab in the treatment of recurrent and metastatic nasopharyngeal carcinoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Cisplatin; Docetaxel; Nimotuzumab

Criteria

Inclusion Criteria:

• biopsy proved nasopharyngeal carcinoma;

• stage IVc according to Union for International Cancer Control (UICC) edition VIII,or recurrent disease after chemotherapy and/or radiotherapy;

• 18 years or older; without other malignancy;

• proper functioning of the major organs.

Exclusion Criteria:

• allergic to docetaxel or cisplatin or Nimotuzumab ;

• female within gestation period or lactation;

• patients received drug of other clinical trail within 3 months